Adding pembrolizumab to docetaxel did not significantly improve outcomes in previously treated patients with mCRPC.

Xencor's stock drops 65%, hitting all-time lows. Focus shifts to autoimmune research, but no near-term catalysts. Read why ...

Pluvicto, a prostate cancer drug, has gained expanded approval that triples the number of patients with metastatic disease ...

The sector has seen billions in merger and acquisition activity in recent years; a September 2024 analysis by Insight ...

The radiopharmaceutical lutetium 177 can be used after radium 223 to treat metastatic castration-resistant prostate cancer.

Explore JANX's promising early data in prostate cancer immunotherapy. Understand market challenges, buyout rumors, and ...

Elevated circulating tumor DNA (ctDNA) fraction and tumor suppressor gene loss are associated with worse prognosis in patients with prostate cancer liver metastases (PCLM), accord ...

Bayer today showcased significant advancements in its pharmaceutical growth strategy and pipeline at its recent annual Pharma ...

Guidelines created by a multi-disciplinary panel of specialists focus on implementation of novel treatments and technologies for which level 1 evidence is lacking.